Pomalong 4 mg Capsule 21's belongs to the group of immunomodulatory drugs used to treat a type of blood cancer called multiple myeloma in adults 18 years or older. Multiple myeloma, also known as myeloma, is a type of bone marrow cancer that affects several areas of the body, such as the spine, skull, pelvis, and ribs.

Pomalong 4 mg Capsule 21's contains Pomalidomide. Pomalidomide is both a targeted therapy drug and an immunotherapy drug. It works in several different ways. It can help the immune system attack and destroy cancer cells (immune system modulator); it kills or stops cancer cells' growth (cancer growth inhibitor). On the other side, it can block the development of new blood vessels, which cancer cells need to grow and spread (angiogenesis inhibitor).

Pomalong 4 mg Capsule 21's is a prescription-only medicine. Take Pomalong 4 mg Capsule 21's as prescribed. Pomalong 4 mg Capsule 21's may be taken with or without food. In some cases, Pomalong 4 mg Capsule 21's may cause certain common side effects such as nausea, rash or allergic reactions, breathing problems, infection, low blood counts, bruising, chest pain, constipation, confusion, dizziness, diarrhoea, fever, faintness, and headaches. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if any of these side effects persist or worsen.

Before taking the Pomalong 4 mg Capsule 21's, inform your doctor about all your allergic or hypersensitivity reactions to medicines or food. Pomalong 4 mg Capsule 21's can cause fetal harm when administered to a pregnant woman. It is critical not to become pregnant or get pregnant while undergoing therapy and for several months afterwards. Before beginning treatment, discuss effective contraception with your healthcare professional. Inform them immediately if you or your partner becomes pregnant while undergoing therapy. Breastfeeding is usually not advised during this treatment since it is unknown whether this medication passes into breast milk. 

Pomalong 4 mg Capsule 21's contains Pomalidomide. It is both a targeted therapy drug and an immunotherapy drug. It works in several different ways. It can assist the immune system in attacking and destroying cancer cells (immune system modulator) and kill or stop cancer cell growth (cancer growth inhibitor). On the other hand, it can prevent the formation of new blood vessels, which cancer cells require in order to grow and spread (angiogenesis inhibitor).

Before taking Pomalong 4 mg Capsule 21's, inform your doctor about your medical history and other medications you are currently taking to rule out any potential negative effects. Avoid taking Pomalong 4 mg Capsule 21's if you are pregnant or breastfeeding or allergic to any component present in Pomalong 4 mg Capsule 21's. Both women and men using this Pomalong 4 mg Capsule 21's should use birth control to avoid pregnancy. Inform your doctor if you have a history of infections; your doctor will closely monitor and manage it. Pomalidomide can lower the number of red blood cells, white blood cells, and platelets in the blood. Anaemia and weariness can result from a low red blood cell count. A blood transfusion may be required if you are anaemic. A low white blood cell count increases the risk of infection, necessitating additional precautions such as rigorous hand washing and avoiding infected people. A fever or temperature of 37⁰ C or above indicates infection. If a patient's temperature is 38⁰ C or higher, medical attention should be sought right away.

• Monitoring of complete blood count while taking Pomalong 4 mg Capsule 21's is advised.
• Drink plenty of fluids to prevent urinary problems.
• If you are due to have any surgery, inform the doctor that you are taking Pomalong 4 mg Capsule 21's.
• Insomnia or difficulty sleeping at night is a common side effect of Pomalidomide. This may be minimised by taking Pomalidomide in the morning.
• Women who are being given Pomalong 4 mg Capsule 21's should use effective contraception during treatment and for three months after treatment.